Literature DB >> 21565241

Co-immunization with interlukin-18 enhances the protective efficacy of liposomes encapsulated recombinant Cu-Zn superoxide dismutase protein against Brucella abortus.

Harisankar Singha1, Amirul Islam Mallick, Chandrakanta Jana, Nishat Fatima, Mohammad Owais, Pallab Chaudhuri.   

Abstract

Brucellosis is a worldwide zoonotic disease caused by Brucella abortus and a number of closely related species. Brucellosis has severe impact on the health and economic prosperity of the developing countries due to the persistent nature of infection and unavailability of effective control measures. The Cu-Zn superoxide dismuatse (SOD) protein of Brucella have been extensively studied as a major antigen involved in bacterial evading mechanism of host defence. Being a critical pro-inflammatory cytokine interleukin-18 (IL-18) plays key role in induction of immune mediated protection against intracellular pathogens. In the present study, we aimed to investigate the immunogenic potential of fusogenic liposomes (escheriosomes) encapsulated recombinant Cu-Zn SOD (rSOD) protein alone or in combination with recombinant IL-18 (rIL-18). Escheriosomes encapsulated rSOD mediated immune responses were further increased upon co-immunization with rIL-18. Furthermore, immunization with escheriosomes encapsulated rSOD alone or in combination with rIL-18, increased resistance in mice against challenge with B. abortus 544.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21565241     DOI: 10.1016/j.vaccine.2011.04.088

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  Liposomes as vaccine delivery systems: a review of the recent advances.

Authors:  Reto A Schwendener
Journal:  Ther Adv Vaccines       Date:  2014-11

2.  Structural, Functional, and Immunogenic Insights on Cu,Zn Superoxide Dismutase Pathogenic Virulence Factors from Neisseria meningitidis and Brucella abortus.

Authors:  Ashley J Pratt; Michael DiDonato; David S Shin; Diane E Cabelli; Cami K Bruns; Carol A Belzer; Andrew R Gorringe; Paul R Langford; Louisa B Tabatabai; J Simon Kroll; John A Tainer; Elizabeth D Getzoff
Journal:  J Bacteriol       Date:  2015-10-12       Impact factor: 3.490

Review 3.  Prophylactic vaccine delivery systems against epidemic infectious diseases.

Authors:  Chao Pan; Hua Yue; Li Zhu; Guang-Hui Ma; Heng-Liang Wang
Journal:  Adv Drug Deliv Rev       Date:  2021-07-17       Impact factor: 17.873

Review 4.  Recent advances in Brucella abortus vaccines.

Authors:  Elaine M S Dorneles; Nammalwar Sriranganathan; Andrey P Lage
Journal:  Vet Res       Date:  2015-07-08       Impact factor: 3.683

Review 5.  Immunotherapy for Bone and Soft Tissue Sarcomas.

Authors:  Takenori Uehara; Tomohiro Fujiwara; Ken Takeda; Toshiyuki Kunisada; Toshifumi Ozaki; Heiichiro Udono
Journal:  Biomed Res Int       Date:  2015-06-17       Impact factor: 3.411

6.  Meta-Analysis and Advancement of Brucellosis Vaccinology.

Authors:  Tatiane F Carvalho; João Paulo A Haddad; Tatiane A Paixão; Renato L Santos
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

Review 7.  Evaluation of Brucellosis Vaccines: A Comprehensive Review.

Authors:  Mohsen Heidary; Shirin Dashtbin; Roya Ghanavati; Marzie Mahdizade Ari; Narjess Bostanghadiri; Atieh Darbandi; Tahereh Navidifar; Malihe Talebi
Journal:  Front Vet Sci       Date:  2022-07-18

8.  Immunogenicity of chimeric MUC1-HER2 vaccine against breast cancer in mice.

Authors:  Elaheh Gheybi; Ali Hatef Salmanian; Abbas Ali Imani Fooladi; Jafar Salimian; Hamideh Mahmoodzadeh Hosseini; Raheleh Halabian; Jafar Amani
Journal:  Iran J Basic Med Sci       Date:  2018-01       Impact factor: 2.699

Review 9.  Development and trial of vaccines against Brucella.

Authors:  Jonathan Lalsiamthara; John Hwa Lee
Journal:  J Vet Sci       Date:  2017-08-31       Impact factor: 1.672

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.